2-(Piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine

Catalog No. :
ACXITW524
CAS No. :
1422060-93-2
Molecular Formula :
C15H21N5
Molecular Weight :
271.37

IUPAC Name:2-(piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine

2-(Piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$82.00Login to see priceIn stockInquiry
100mg95%$119.00Login to see priceIn stockInquiry
250mg95%$202.00Login to see priceIn stockInquiry
1g95%$797.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(Piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine
IUPAC Name2-(piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine
MDL No.MFCD30185267
Molecular FormulaC15H21N5
Molecular Weight271.37
SMILESC12=NC(C3CCNCC3)=NN1C=C(N4CCCC4)C=C2
InChI KeyFWDBHCFWFYTGOA-UHFFFAOYSA-N
Synonym2-(piperidin-4-yl)-6-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridine;[1,2,4]Triazolo[1,5-a]pyridine, 2-(4-piperidinyl)-6-(1-pyrrolidinyl)-
CAS No.1422060-93-2
PubChem CID121229443

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACXITW524 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXITW524 route product structure diagram
    ACXITW5241422060-93-2 In Stock
Inquiry

2. ACXITW524 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXITW524 route product structure diagram
    ACXITW5241422060-93-2 In Stock
Inquiry

Comments (0)